Clinical Trials
236
Trial Phases
5 Phases
Drug Approvals
14
Drug Approvals
Teneligliptin Hydrobromide Tablets
- Product Name
- 泰里安
- Approval Number
- 国药准字HJ20210064
- Approval Date
- Aug 3, 2021
Diltiazem Hydrochloride for Injection
- Product Name
- 合贝爽
- Approval Number
- 国药准字HJ20160287
- Approval Date
- Nov 17, 2020
Diltiazem Hydrochloride for Injection
- Product Name
- 合贝爽
- Approval Number
- 国药准字HJ20160285
- Approval Date
- Nov 17, 2020
Diltiazem Hydrochloride for Injection
- Product Name
- 合贝爽
- Approval Number
- 国药准字HJ20160286
- Approval Date
- Nov 17, 2020
Diltiazem Hydrochloride for Injection
- Product Name
- 合贝爽
- Approval Number
- 国药准字HJ20160284
- Approval Date
- Nov 17, 2020
Dexamethasone Palmitate Injection
- Product Name
- 多力生
- Approval Number
- 国药准字HJ20160167
- Approval Date
- Jul 14, 2020
Dexamethasone Palmitate Injection
- Product Name
- 多力生
- Approval Number
- 国药准字HJ20160168
- Approval Date
- Jul 14, 2020
- Prev
- 1
- 2
- Next
Clinical Trials
Distribution across different clinical trial phases (193 trials with phase data)• Click on a phase to view related trials
The Purpose of This Study is to Investigate the Safety, Tolerability and Pharmacokinetics of MT-7117 in Healthy Subjects.
- First Posted Date
- 2025-05-29
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 40
- Registration Number
- NCT06994286
- Locations
- 🇨🇳
Beijing Anzhen Hospital, Capital Medical University, Beijing, Beijing, China
Clinical Pharmacology Study of MT-3534 in Healthy Adult Male Volunteers
- Conditions
- Healthy Adult Male Volunteers
- Interventions
- Biological: Placebo
- First Posted Date
- 2024-07-01
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 56
- Registration Number
- NCT06482346
- Locations
- 🇯🇵
Clinical Research Hospital Tokyo, Shinjuku-ku, Tokyo, Japan
An Exploratory Study of MT-2990 in Patients With AAV
- Conditions
- Antineutrophil Cytoplasmic Antibody (ANCA) -Associated Vasculitis (AAV)
- Interventions
- First Posted Date
- 2024-01-09
- Last Posted Date
- 2025-01-16
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 10
- Registration Number
- NCT06196905
- Locations
- 🇯🇵
Hiroshima University Hospital, Hiroshima-shi, Hiroshima, Japan
🇯🇵Kagawa University Hospital, Kita-gun, Kagawa, Japan
🇯🇵Saitama Medical University Hospital, Iruma-gun, Saitama, Japan
A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL
- First Posted Date
- 2022-12-20
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 46
- Registration Number
- NCT05658562
- Locations
- 🇯🇵
Nagoya Medical Center, Nagoya-shi, Aichi, Japan
🇯🇵Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya-shi, Aichi, Japan
🇯🇵National Cancer Center Hospital East, Kashiwa-shi, Chiba, Japan
Extension Study Following the Studies MT-1186-A03 or A04 to Evaluate the Safety of Oral Edaravone in Subjects With ALS
- First Posted Date
- 2022-10-05
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Target Recruit Count
- 15
- Registration Number
- NCT05568615
- Locations
- 🇯🇵
National Hospital Organization Higashinagoya National Hospital, Nagoya-shi, Aichi, Japan
🇯🇵National Hospital Organization Chibahigashi National Hospital, Chiba-shi, Chiba, Japan
🇯🇵Fukushima Medical University Hospital, Fukushima-shi, Fukushima, Japan
- Prev
- 1
- 2
- 3
- 4
- 5
- 30
- Next
News
Mitsubishi Tanabe Pharma America to Present Breakthrough Neurodegenerative Disease Research at AAN 2025
Mitsubishi Tanabe Pharma America will present 11 studies at the American Academy of Neurology 2025 Annual Meeting, including research on investigational ND0612 for Parkinson's disease and RADICAVA formulations for ALS.
GV20 Therapeutics Partners with Mitsubishi Tanabe to Develop Novel AI-Discovered Antibody-Drug Conjugates
GV20 Therapeutics has formed a strategic research collaboration with Mitsubishi Tanabe Pharma Corporation to develop first-in-class antibody-drug conjugates targeting novel tumor antigens.
Edaravone Shows Promise in Targeting TDP-43 Mislocalization in ALS, New Preclinical Research Reveals
Mitsubishi Tanabe Pharma America published new preclinical research demonstrating edaravone's ability to mitigate TDP-43 mislocalization, a hallmark feature in over 97% of sporadic ALS cases.
Real-World Data Analysis Shows Edaravone Associated with Longer Milestone-Free Time in ALS
A real-world data analysis by Mitsubishi Tanabe Pharma America suggests that edaravone is associated with longer disease progression milestone-free time in ALS patients.
Mitsubishi Tanabe Pharma America Presents Real-World Data on RADICAVA ORS® for ALS at NASP 2024
Mitsubishi Tanabe Pharma America (MTPA) presented real-world data on RADICAVA ORS® (edaravone) at the 2024 NASP Annual Meeting, focusing on ALS treatment.
ND0612 Infusion Shows Sustained Reduction in Off-Time for Parkinson's Patients
ND0612, a continuous subcutaneous infusion of levodopa/carbidopa, significantly reduced motor symptom fluctuations in advanced Parkinson's disease over one year.